Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
Article
CAS
Google Scholar
Bilfinger T, Keresztes R, Albano D, Nemesure B. Five-year survival among stage IIIA lung Cancer patients receiving two different treatment modalities. Med Sci Monit. 2016;22:2589–94.
Article
Google Scholar
Xu-Welliver M, Carbone DP. Blood-based biomarkers in lung cancer: prognosis and treatment decisions. Transl Lung Cancer Res. 2017;6:708–12.
Article
Google Scholar
Yi Z, Liu B, Guan X, Ma F. Plasma cell-free DNA and survival in non-small-cell lung cancer: a meta-analysis. Mol Clin Oncol. 2017;7:167–72.
PubMed
PubMed Central
Google Scholar
A.A.Chaudhuri, J.J.Chabon, A.F.Lovejoy, A.M.Newman, H.Stehr, T.D.Azad, M.S.Khodadoust, M.S.Esfahani, C.L.Liu, L.Zhou, F.Scherer, D.M.Kurtz, C.Say, J.N.Carter, D.J.Merriott, J.C.Dudley, M.S.Binkley, L.Modlin, S.K.Padda, M.F.Gensheimer, R.B.West, J.B.Shrager, J.W.Neal, H.A.Wakelee, B.W.Loo, A.A.Alizadeh, M.Diehn, Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling, Cancer Discov.2017) CD-0716.
Xu T, Shen G, Cheng M, Xu W, Shen G, Hu S. Clinicopathological and prognostic significance of circulating tumor cells in patients with lung cancer: a meta-analysis. Oncotarget. 2017;8:62524–36.
PubMed
PubMed Central
Google Scholar
Gallo M, De LA, Maiello MR, D’Alessio A, Esposito C, Chicchinelli N, Forgione L, Piccirillo MC, Rocco G, Morabito A, Botti G, Normanno N. Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. Transl Lung Cancer Res. 2017;6:486–98.
Article
Google Scholar
Gasiorowski L, Dyszkiewicz W, Zielinski P. In-vivo isolation of circulating tumor cells in non-small cell lung cancer patients by CellCollector. Neoplasma. 2017;64(6):938–44.
Article
CAS
Google Scholar
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, Liu L, Lin B, Su H, Zhao L, Su M, Pan H, Shen L, Xie D, Xie C. Evaluation of tumor-derived Exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung Cancer using next-generation sequencing. Clin Cancer Res. 2017;23:5311–9.
Article
CAS
Google Scholar
Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, Roz L, Conte D, Grassi M, Sverzellati N, Marchiano A, Negri E, La VC, Pastorino U. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung Cancer screening: a correlative MILD trial study. J Clin Oncol. 2014;32:768–73.
Article
Google Scholar
Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001;1:46–54.
Article
CAS
Google Scholar
Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev. 2009;28:177–83.
Article
Google Scholar
Giussani M, Landoni E, Merlino G, Turdo F, Veneroni S, Paolini B, Cappelletti V, Miceli R, Orlandi R, Triulzi T, Tagliabue E. Extracellular matrix proteins as diagnostic markers of breast carcinoma. J Cell Physiol. 2018;233:6280–90.
Article
CAS
Google Scholar
Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund LT. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6:209–17.
Article
Google Scholar
Kuchnio A, Moens S, Bruning U, Kuchnio K, Cruys B, Thienpont B, Broux M, Ungureanu AA, Leite de OR, Bruyere F, Cuervo H, Manderveld A, Carton A, Hernandez-Fernaud JR, Zanivan S, Bartic C, Foidart JM, Noel A, Vinckier S, Lambrechts D, Dewerchin M, Mazzone M, Carmeliet P. The Cancer cell oxygen sensor PHD2 promotes metastasis via activation of Cancer-associated fibroblasts. Cell Rep. 2015;12:992–1005.
Article
CAS
Google Scholar
Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211:1503–23.
Article
CAS
Google Scholar
Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009;326:1216–9.
Article
CAS
Google Scholar
White ES. Lung extracellular matrix and fibroblast function. Ann. Am. Thorac. Soc. 2015;12(Suppl 1):S30–3. https://doi.org/10.1513/AnnalsATS.201406-240MG. S30-S33
Article
PubMed
PubMed Central
Google Scholar
Burgess JK, Mauad T, Tjin G, Karlsson JC, Westergren-Thorsson G. The extracellular matrix - the under-recognized element in lung disease? J Pathol. 2016;240:397–409.
Article
CAS
Google Scholar
Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15:1243–53.
Article
CAS
Google Scholar
Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139:891–906.
Article
CAS
Google Scholar
Willumsen N, Bager CL, Leeming DJ, Smith V, Christiansen C, Karsdal MA, Dornan D, Bay-Jensen AC. Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer. Cancer Med. 2014;3:1136–45.
Article
CAS
Google Scholar
Gandellini P, Andriani F, Merlino G, D’Aiuto F, Roz L, Callari M. Complexity in the tumour microenvironment: cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. Semin. Cancer biol. Revised version submitted. 2015;35:96–106.
Article
CAS
Google Scholar
Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu ML, Colombo MP, Balsari A, Menard S, Orlandi R, Tagliabue E. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS One. 2013;8:e56761.
Article
CAS
Google Scholar
Chen Y, Terajima M, Yang Y, Sun L, Ahn YH, Pankova D, Puperi DS, Watanabe T, Kim MP, Blackmon SH, Rodriguez J, Liu H, Behrens C, Wistuba II, Minelli R, Scott KL, Sanchez-Adams J, Guilak F, Pati D, Thilaganathan N, Burns AR, Creighton CJ, Martinez ED, Zal T, Grande-Allen KJ, Yamauchi M, Kurie JM. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest. 2015;125:1147–62.
Article
Google Scholar
M. Giussani, G. Merlino, V. Cappelletti, E. Tagliabue, M.G. Daidone, Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression, Semin Cancer Biol 35:3–10. doi: https://doi.org/10.1016/j.semcancer.2015.09.012. Epub;%2015 Sep 28. (2015) 3–10.
Article
CAS
Google Scholar
Hung JY, Yen MC, Jian SF, Wu CY, Chang WA, Liu KT, Hsu YL, Chong IW, Kuo PL. secreted protein acidic and rich in cysteine (SPARC) induces cell migration and epithelial mesenchymal transition through WNK1/snail in non-small cell lung cancer. Oncotarget. 2017;8:63691–702.
PubMed
PubMed Central
Google Scholar
Tichet M, Prod’Homme V, Fenouille N, Ambrosetti D, Mallavialle A, Cerezo M, Ohanna M, Audebert S, Rocchi S, Giacchero D, Boukari F, Allegra M, Chambard JC, Lacour JP, Michiels JF, Borg JP, Deckert M, Tartare-Deckert S. Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. Nat Commun. 2015;6:6993. https://doi.org/10.1038/ncomms7993. 6993
Article
CAS
PubMed
Google Scholar
Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, Sage EH. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 2003;63:5376–80.
CAS
PubMed
Google Scholar
Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108:3713–8.
Article
CAS
Google Scholar
Andriani F, Bertolini G, Facchinetti F, Baldoli E, Moro M, Casalini P, Caserini R, Milione M, Leone G, Pelosi G, Pastorino U, Sozzi G, Roz L. Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. Mol Oncol. 2016;10:253–71.
Article
CAS
Google Scholar
M.E. Ritchie, B. Phipson, D. Wu, Y. Hu, C.W. Law, W. Shi, G.K. Smyth, limma powers differential expression analyses for RNA-sequencing and microarray studies, nucleic acids res. %20;43 (2015) e47.
Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551–61.
Article
CAS
Google Scholar
Jia D, Liu Z, Deng N, Tan TZ, Huang RY, Taylor-Harding B, Cheon DJ, Lawrenson K, Wiedemeyer WR, Walts AE, Karlan BY, Orsulic S. A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett. 2016;382:203–14.
Article
CAS
Google Scholar
Garcia-Pravia C, Galvan JA, Gutierrez-Corral N, Solar-Garcia L, Garcia-Perez E, Garcia-Ocana M, Del Amo-Iribarren J, Menendez-Rodriguez P, Garcia-Garcia J, de Jr LT, Simon-Buela L, Barneo L. Overexpression of COL11A1 by cancer-associated fibroblasts: clinical relevance of a stromal marker in pancreatic cancer. PLoS One. 2013;8:e78327.
Article
CAS
Google Scholar
Shen L, Yang M, Lin Q, Zhang Z, Zhu B, Miao C. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep. 2016;36:877–85.
Article
CAS
Google Scholar
M.Karaglani, I.Toumpoulis, N.Goutas, N.Poumpouridou, D.Vlachodimitropoulos, S.Vasilaros, I.Rizos, C.Kroupis, Development of novel real-time PCR methodology for quantification of COL11A1 mRNA variants and evaluation in breast cancer tissue specimens, BMC Cancer 15:694. doi: https://doi.org/10.1186/s12885-015-1725-8. (2015) 694–1725.
Chong IW, Chang MY, Chang HC, Yu YP, Sheu CC, Tsai JR, Hung JY, Chou SH, Tsai MS, Hwang JJ, Lin SR. great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Oncol Rep. 2006;16:981–8.
CAS
PubMed
Google Scholar
de Torres JP, Casanova C, Pinto-Plata V, Varo N, Restituto P, Cordoba-Lanus E, Baz-Davila R, guirre-Jaime A, Celli BR. Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study, PLoS. ONE. 2011;6:e16021.
Article
CAS
Google Scholar
Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG, Klinge CM. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells, Endocr. Relat Cancer. 2006;13:113–34.
Article
CAS
Google Scholar
Li Z, Li AD, Xu L, Bai DW, Hou KZ, Zheng HC, Qu XJ, Liu YP. SPARC expression in gastric cancer predicts poor prognosis: results from a clinical cohort, pooled analysis and GSEA assay. Oncotarget. 2016;7:70211–22.
PubMed
PubMed Central
Google Scholar
Chen ZY, Zhang JL, Yao HX, Wang PY, Zhu J, Wang W, Wang X, Wan YL, Chen SW, Chen GW, Liu YC. Aberrant methylation of the SPARC gene promoter and its clinical implication in Gastric Cancer. Sci Rep. 2014;4:7035. https://doi.org/10.1038/srep07035. 7035
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang HY, Li YY, Shao Q, Hou JH, Wang F, Cai MB, Zeng YX, Shao JY. Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis. J Transl. Med. 2012;10:27. https://doi.org/10.1186/1479-5876-10-27. 27–10
Article
CAS
PubMed
PubMed Central
Google Scholar
Wong SL, Sukkar MB. The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease. Br J Pharmacol. 2017;174:3–14.
Article
CAS
Google Scholar
Y.Huang, J.Zhang, Y.Y.Zhao, W.Jiang, C.Xue, F. Xu, H.Y. Zhao, Y. Zhang, L.P. Zhao, Z.H. Hu, z.W. Yao, Q.Y. Liu, L. Zhang, SPARC expression and prognostic value in non-small cell lung cancer, Chin J Cancer 31 (2012) 541–548.
Edlund K, Lindskog C, Saito A, Berglund A, Ponten F, Goransson-Kultima H, Isaksson A, Jirstrom K, Planck M, Johansson L, Lambe M, Holmberg L, Nyberg F, Ekman S, Bergqvist M, Landelius P, Lamberg K, Botling J, Ostman A, Micke P. CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int J Cancer. 2012;131(10):2264–73.
Article
CAS
Google Scholar
Tripodo C, Burocchi A, Piccaluga PP, Chiodoni C, Portararo P, Cappetti B, Botti L, Gulino A, Isidori A, Liso A, Visani G, Martelli MP, Falini B, Pandolfi PP, Colombo MP, Sangaletti S. Persistent immune stimulation exacerbates genetically driven myeloproliferative disorders via stromal remodeling. Cancer Res. 2017;77:3685–99.
Article
CAS
Google Scholar
Sangaletti S, Tripodo C, Santangelo A, Castioni N, Portararo P, Gulino A, Botti L, Parenza M, Cappetti B, Orlandi R, Tagliabue E, Chiodoni C, Colombo MP. Mesenchymal transition of high-grade breast carcinomas depends on extracellular matrix control of myeloid suppressor cell activity. Cell Rep. 2016;17:233–48.
Article
CAS
Google Scholar
Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346–54.
Article
CAS
Google Scholar